Anetoderma and its prothrombotic abnormalities

Journal of the American Academy of Dermatology

Volumn 49, Issue 6, 2003, Pages 1008-1012

  Sparsa, Agnes ^a   Piette, Jean Charles ^a   Wechsler, Bertrand ^a   Amoura, Zahir ^a   Francès, Camille ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ADOLESCENT; ADULT; ANETODERMA; ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOLOGICAL PARAMETERS; LABORATORY TEST; MALE; PATIENT REFERRAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCREENING; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; UNIVERSITY;

EID: 0344430224     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(03)02110-8     Document Type: Article

References (21)

1. Jadassohn J. Ueber eire eigenartige form von [prime] atrophia maculosa cutis. Arch Dermatol Syph 1892;11:342-58.
2. Venencie PY, Winkelmann RK, Moore BA. Anetoderma. Clinical findings, associations and long-term follow-up evaluations. Arch Dermatol 1984;120:1032-9.
3. Disdier P, Harlé JR, Andrac L, Verrot D, Bolla G, San Marco M, et al. Primary anetoderma associated with the antiphospholipid syndrome. J Am Acad Dermatol 1994;30:133-4.
4. Francěs C, Piette JC. Cutaneous manifestations of Hughes syndrome occurring in the context of lupus erythematosus. Lupus 1997;6:139-44.
5. Tan EM, Cohen AS, Fries J, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-77.
6. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Report of an international workshop. Arthritis Rheum 1999;42:1309-11.
7. Piette JC, Weschler B, Francěs C, Papo T, Godeau P. Exclusion criteria for primary antiphospholipid syndrome. J Rheumatol 1993;20:1802-4.
8. Montilla C, Alarcon-Segovia D. Anetoderma in systemic lupus erythematosus; relationship to antiphospholipid antibodies. Lupus 2000;9:545-7.
9. Romani J, Perez F, Llobet M, Planaguma M, Pujol RM. Anetoderma associated with antiphsopholipid antibodies: case report and review of the literature. J Eur Acad Dermatol Venereol 2000;15:175-8.
10. Nesher G, Hany J, Rosenmann D, Abraham AS. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features and treatment. Semin Arthritis Rheum 1997;27:27-35.
11. Venencie PY, Winkelmann RK. Histopathologic findings in anetoderma. Arch Dermatol 1984;120:1040-4.
12. Rao AK, Kaplan R, Sheth S. Inherited thrombophilic states. Semin Thromb Hemost 1998;24(suppl 1):3-12.
13. Stephansson EA, Niemi KM, Jouhikainen T, Vaarala O, Palosuo T. Lupus anticoagulant and the skin. A long term follow-up study of SLE patients with special reference to histopathological findings. Acta Derm Venereol (Stockh) 1991;71:416-22.
14. Lindstrom J, Smith KJ, Skelton HG, Redfield R, Alving BM, Wagner KF, et al. Increased anticardiolipin antibodies associated with the development of anetoderma in HIV-disease. Int J Dermatol 1995;34:408-15.
15. Prizant TL, Lucky AW, Frieden IJ, Burton PS, Suarez SM. Spontaneous atrophic patches in extremely premature infants: anetoderma of prematurity. Arch Dermatol 1996;132:671-74.
16. Venencie PY, Bonnefoy A, Gogly B, Groult N, Kut C, Pellat B, et al. Increased expression of gelatinase A and B by skin explants from patients with anetoderma. Br J Dermatol 1997;137:517-25.
17. Ghomrasseni S, Dridi M, Gogly B, Bonnefoix M, Vabres P, Venencie PY, et al. Anetoderma: an altered balance between metalloproteinases and tissue inhibitors of metalloproteinases. Am J Dermatopathol 2002;24:118-29.
18. Zalewska T, Ziemka-Nalecz M, Sarnowska A, Domanska-Janik K. Involvement of MMPs in delayed neuronal death after global ischemia. Acta Neurobiol Exp (Warsz) 2002;62:53-61.
19. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002;106:1543-9.
20. Ben-Yosef Y, Lahat N, Shapiro S, Bitterman H, Miller A. Regulation of endothelial matrix metalloproteinase-2 by hypoxia/reoxygenation. Circ Res 2002;90:784-91.
21. Zhang X, Sakamoto T, Hata Y, Kubota T, Hisatomi T, Murata T, et al. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats. Exp Eye Res 2002;74:577-84.